不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
第 100 天抑制性 KIR2DL2 与激活性 NKp30 NK 细胞绝对数恢复可预测淋巴瘤自体干细胞移植后生存
英文原题：Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas.
查看英文原题
Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在接受自体外周血造血干细胞移植（APBHSCT）的淋巴瘤患者中，输注的自体移植物中抑制性杀伤细胞免疫球蛋白样受体（KIR）2DL2和激活性自然杀伤（NK）p30细胞的绝对数量是临床结局的预测因素。为了评估这些NK细胞亚群的长期恢复是否仍具有临床相关性，我们着手研究它们在APBHSCT后第100天时的预后能力。这是一项回顾性单机构研究，纳入了来自我们先前III期试验的107例患者，这些患者在APBHSCT后第100天时进行了临床评估。从第100天起的中位随访时间为168.19个月（四分位距：156.85-181.28个月）。第100天时抑制性KIR2DL2 < 0.08个细胞/L且激活性NKp30 0.19个细胞/L的患者获得了更优的总生存期（OS）和无进展生存期（PFS）。
多因素分析显示，第100天时的抑制性KIR2DL2 [OS：HR = 1.449，95%CI，1.231-1.895，p < 0.013；PFS：HR = 2.069，95%CI，1.134-3.775，p < 0.021] 和激活性NKp30 [OS：HR = 4.985，95%CI，2.614-9.506，p < 0.0001；PFS：HR = 4.661，95%CI，2.598-8.393，p < 0.0001] 均是OS和PFS的独立预测因素。第100天时的抑制性KIR2DL2和激活性NKp30 NK细胞是接受APBHSCT治疗的淋巴瘤患者的预后免疫生物标志物。
展开英文摘要原文
The infusion autograft absolute number of inhibitory killer immunoglobulin-like receptor (KIR) 2DL2 and activating natural killer (NK)p30 cells are predictors of clinical outcomes in lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). To assess if the long-term recovery of these NK cell subsets still holds clinical relevance, we set up to investigate their prognostic ability at day 100 post-APBHSCT. This was a retrospective single-institution study including 107 patients from our prior phase III trial who had a clinical assessment at day 100 post-APBHSCT. The median follow-up from day 100 was 168. 19 months (interquartile range: 156.
85-181. 28 months). Patients with day 100 inhibitory KIR2DL2 < 0. 08 cells/ L and activating NKp30 0. 19 cells/ L experienced superior overall survival (OS) and progression-free survival (PFS). A multivariate analysis revealed both the day 100 inhibitory KIR2DL2 [OS: HR = 1. 449, 95%CI, 1. 231-1. 895, p < 0. 013; and PFS: HR = 2. 069, 95%CI, 1.
134-3. 775, p < 0. 021] and activating NKp30 [OS: HR = 4. 985, 95%CI, 2. 614-9. 506, p < 0. 0001; and PFS: HR = 4. 661, 95%CI, 2. 598-8. 393, p < 0. 0001] were independent predictors for OS and PFS. Inhibitory KIR2DL2 and activating NKp30 NK cells at day 100 are prognostic immune biomarkers in lymphoma patients treated with APBHSCT.
论文信息
- 作者
- Porrata LF、Ansell SM、Micallef IN、Johnston PB、Villasboas JC、Paludo J、Durani U、Markovic SN
- 第一作者单位
- Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.United States
- 通讯作者单位
- Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.United States
- 期刊
- Biomedicines2024 Aug 9
- 原文标识
- PubMed 39200272 · DOI 10.3390/biomedicines12081808
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →